Novo Nordisk A/S

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 164.3B. In comparison, LLY has a market cap of 884B. Regarding current trading prices, NVO is priced at $36.98, while LLY trades at $935.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.44, whereas LLY's P/E ratio is 40.70. In terms of profitability, NVO's ROE is +0.61%, compared to LLY's ROE of +0.98%. Regarding short-term risk, NVO is more volatile compared to LLY. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check LLY's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 164.3B. In comparison, JNJ has a market cap of 585.7B. Regarding current trading prices, NVO is priced at $36.98, while JNJ trades at $243.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.44, whereas JNJ's P/E ratio is 22.03. In terms of profitability, NVO's ROE is +0.61%, compared to JNJ's ROE of +0.34%. Regarding short-term risk, NVO is more volatile compared to JNJ. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check JNJ's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 164.3B. In comparison, ABBV has a market cap of 369.2B. Regarding current trading prices, NVO is priced at $36.98, while ABBV trades at $208.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.44, whereas ABBV's P/E ratio is 88.10. In terms of profitability, NVO's ROE is +0.61%, compared to ABBV's ROE of -3.62%. Regarding short-term risk, NVO is more volatile compared to ABBV. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check ABBV's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 164.3B. In comparison, MRK has a market cap of 298.8B. Regarding current trading prices, NVO is priced at $36.98, while MRK trades at $120.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.44, whereas MRK's P/E ratio is 16.63. In terms of profitability, NVO's ROE is +0.61%, compared to MRK's ROE of +0.36%. Regarding short-term risk, NVO is more volatile compared to MRK. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check MRK's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 164.3B. In comparison, NVS has a market cap of 297.8B. Regarding current trading prices, NVO is priced at $36.98, while NVS trades at $154.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.44, whereas NVS's P/E ratio is 21.54. In terms of profitability, NVO's ROE is +0.61%, compared to NVS's ROE of +0.33%. Regarding short-term risk, NVO is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check NVS's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 164.3B. In comparison, AMGN has a market cap of 187.6B. Regarding current trading prices, NVO is priced at $36.98, while AMGN trades at $347.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.44, whereas AMGN's P/E ratio is 24.43. In terms of profitability, NVO's ROE is +0.61%, compared to AMGN's ROE of +0.97%. Regarding short-term risk, NVO is more volatile compared to AMGN. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check AMGN's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 164.3B. In comparison, GILD has a market cap of 173.4B. Regarding current trading prices, NVO is priced at $36.98, while GILD trades at $139.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.44, whereas GILD's P/E ratio is 17.14. In terms of profitability, NVO's ROE is +0.61%, compared to GILD's ROE of +0.41%. Regarding short-term risk, NVO is more volatile compared to GILD. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check GILD's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 164.3B. In comparison, PFE has a market cap of 161.1B. Regarding current trading prices, NVO is priced at $36.98, while PFE trades at $28.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.44, whereas PFE's P/E ratio is 20.83. In terms of profitability, NVO's ROE is +0.61%, compared to PFE's ROE of +0.09%. Regarding short-term risk, NVO is more volatile compared to PFE. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check PFE's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 164.3B. In comparison, AZN has a market cap of 157.7B. Regarding current trading prices, NVO is priced at $36.98, while AZN trades at $203.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.44, whereas AZN's P/E ratio is 31.16. In terms of profitability, NVO's ROE is +0.61%, compared to AZN's ROE of +0.23%. Regarding short-term risk, NVO is more volatile compared to AZN. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check AZN's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 164.3B. In comparison, BMY has a market cap of 121.4B. Regarding current trading prices, NVO is priced at $36.98, while BMY trades at $59.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.44, whereas BMY's P/E ratio is 17.23. In terms of profitability, NVO's ROE is +0.61%, compared to BMY's ROE of +0.39%. Regarding short-term risk, NVO is more volatile compared to BMY. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check BMY's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 164.3B. In comparison, SNY has a market cap of 116.6B. Regarding current trading prices, NVO is priced at $36.98, while SNY trades at $47.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.44, whereas SNY's P/E ratio is 20.55. In terms of profitability, NVO's ROE is +0.61%, compared to SNY's ROE of +0.11%. Regarding short-term risk, NVO is more volatile compared to SNY. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check SNY's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 164.3B. In comparison, GSK has a market cap of 114.2B. Regarding current trading prices, NVO is priced at $36.98, while GSK trades at $56.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.44, whereas GSK's P/E ratio is 15.40. In terms of profitability, NVO's ROE is +0.61%, compared to GSK's ROE of +0.30%. Regarding short-term risk, NVO is more volatile compared to GSK. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check GSK's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 164.3B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, NVO is priced at $36.98, while HZNP trades at $116.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.44, whereas HZNP's P/E ratio is 61.86. In terms of profitability, NVO's ROE is +0.61%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, NVO is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check HZNP's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 164.3B. In comparison, BIIB has a market cap of 26B. Regarding current trading prices, NVO is priced at $36.98, while BIIB trades at $177.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.44, whereas BIIB's P/E ratio is 20.15. In terms of profitability, NVO's ROE is +0.61%, compared to BIIB's ROE of +0.07%. Regarding short-term risk, NVO is more volatile compared to BIIB. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check BIIB's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 164.3B. In comparison, GRFS has a market cap of 7B. Regarding current trading prices, NVO is priced at $36.98, while GRFS trades at $8.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.44, whereas GRFS's P/E ratio is 13.08. In terms of profitability, NVO's ROE is +0.61%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, NVO is more volatile compared to GRFS. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check GRFS's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 164.3B. In comparison, OGN has a market cap of 1.7B. Regarding current trading prices, NVO is priced at $36.98, while OGN trades at $6.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.44, whereas OGN's P/E ratio is 8.83. In terms of profitability, NVO's ROE is +0.61%, compared to OGN's ROE of +0.26%. Regarding short-term risk, NVO is less volatile compared to OGN. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check OGN's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 164.3B. In comparison, CELG-RI has a market cap of 243.2M. Regarding current trading prices, NVO is priced at $36.98, while CELG-RI trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.44, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, NVO's ROE is +0.61%, compared to CELG-RI's ROE of +0.39%. Regarding short-term risk, NVO is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check CELG-RI's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 164.3B. In comparison, SCLX has a market cap of 63.6M. Regarding current trading prices, NVO is priced at $36.98, while SCLX trades at $7.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.44, whereas SCLX's P/E ratio is -0.18. In terms of profitability, NVO's ROE is +0.61%, compared to SCLX's ROE of +1.81%. Regarding short-term risk, NVO is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check SCLX's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 164.3B. In comparison, CTOR has a market cap of 62.1M. Regarding current trading prices, NVO is priced at $36.98, while CTOR trades at $0.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.44, whereas CTOR's P/E ratio is -2.27. In terms of profitability, NVO's ROE is +0.61%, compared to CTOR's ROE of -0.55%. Regarding short-term risk, NVO is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check CTOR's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 164.3B. In comparison, MIRA has a market cap of 46.5M. Regarding current trading prices, NVO is priced at $36.98, while MIRA trades at $1.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.44, whereas MIRA's P/E ratio is -0.82. In terms of profitability, NVO's ROE is +0.61%, compared to MIRA's ROE of -6.46%. Regarding short-term risk, NVO is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check MIRA's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 164.3B. In comparison, SRXH has a market cap of 4.6M. Regarding current trading prices, NVO is priced at $36.98, while SRXH trades at $0.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.44, whereas SRXH's P/E ratio is -0.80. In terms of profitability, NVO's ROE is +0.61%, compared to SRXH's ROE of +4.36%. Regarding short-term risk, NVO is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check SRXH's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 164.3B. In comparison, SCLXW has a market cap of 1.1M. Regarding current trading prices, NVO is priced at $36.98, while SCLXW trades at $0.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.44, whereas SCLXW's P/E ratio is N/A. In terms of profitability, NVO's ROE is +0.61%, compared to SCLXW's ROE of +1.81%. Regarding short-term risk, NVO is less volatile compared to SCLXW. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check SCLXW's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 164.3B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, NVO is priced at $36.98, while BDSIW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.44, whereas BDSIW's P/E ratio is N/A. In terms of profitability, NVO's ROE is +0.61%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, NVO is less volatile compared to BDSIW. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check BDSIW's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 164.3B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, NVO is priced at $36.98, while CRXT trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.44, whereas CRXT's P/E ratio is -0.02. In terms of profitability, NVO's ROE is +0.61%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, NVO is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check CRXT's competition here